ASRS 2023: What research is most exciting? Our interviewees give their opinions.
"What research at the 2023 ASRS meeting do you find exciting or interesting?" Here's what Aaron Lee, MD, Megan Baldwin, PhD, and Carl Danzig, MD had to say!
ZEISS Medical Technology previews refractive workflow innovations ahead of ESCRS annual meeting
Advancements from Carl Zeiss Medical AG in the cataract and cornea space include a new intraocular lens and therapeutic laser enhancements.
WIO 2023: Dr Maria H. Berrocal on robots, 3D surgery and the future of surgical retina
Maria H. Berrocal, MD, spoke with our team about her presentation at the Women in Ophthalmology Summer Symposium in Marco Island, Florida.
Johnson & Johnson Vision to launch ELITA Platform during ESCRS 2023
The new platform incorporates the SILK procedure, allowing surgeons to perform refractive correction on patients with myopia.
ESCRS celebrates dual milestones for EUREQUO Registry
The EUREQUO Annual Report celebrates 15 years and over 4 million surgical procedures in the registry.
BREAKING: US FDA issues CRL for Outlook Therapeutics’ ONS-5010
According to the company, it is working with the FDA to address the agency’s issues.
WIO 2023: ICL and clear lens exchange
Eva Kim, MD, spoke with our team to share insights from her presentation on ICL versus CLE at the Women in Ophthalmology Summer Symposium 2023 in Marco Island, Florida.
Atsena Therapeutics doses first patient in Phase I/II clinical trial of ATSN-201 for treatment of x-linked retinoschisis
ATSN-201 leverages novel spreading capsid to overcome challenges associated with intravitreally delivered AAVs in the treatment of XLRS.
Imaging trends in paediatric uveitis
OCT methods are invaluable in the assessment of patients with the condition
Immunosuppressants used to control ocular inflammation not involved in cancer development
Commonly used immunosuppressants used in the short term to control an ocular inflammatory disease were not associated with increased risk of developing cancer later.
Cutting-edge advances in corneal treatment
Surgeon discusses latest trends for treating cornea
Kiora Pharmaceuticals granted European and US patents for local ocular delivery of the KIO-100 family of compounds
This intellectual property protects Kiora's pipeline by covering several inflammatory-related therapeutic applications, including posterior non-infectious uveitis.
Lenticule extraction in hyperopia – an update
A multicentre study demonstrates comparable results to FS-LASIK
EMA approves Clinical Trial Application for retinitis pigmentosa therapy from ViGeneron
VG901 is a gene therapy for CNGA1-associated RP.
Retina biomarkers identified 7 years before clinical diagnosis of Parkinson disease
Researchers have identified markers that indicate the presence of Parkinson disease in patients an average of 7 years before the disease presents clinically.
Macular retinal detachment development associated with myopic foveoschisis
The first-line treatment to avoid visual impairment for these cases is anti-vascular endothelial growth factor therapy (VEGF).
EMA accepts Iveric Bio’s avacincaptad pegol (ACP) for MAA review
The geographic atrophy treatment was approved by the FDA in the US earlier this month.
Recap: European Society of Ophthalmology turns Prague into the ‘focal point’ of eye care
The 2023 SOE meeting featured symposia, awards and a spotlight on young ophthalmologists
Better IOL calculation in post-LASIK eyes
To heighten precision, use total keratometry, not imaginary numbers
Sandoz releases positive results for biosimilar aflibercept in MYLIGHT Phase III study
The study met its primary efficacy endpoint for the neovascular age-related macular degeneration (nAMD) treatment.
Surgical management of posterior uveitis in children
Vitrectomy is a tool that can help surgeons curb complications
ASRS 2023: Megan Baldwin, CEO of Opthea Limited, shares updates on sozinibercept
Megan Baldwin, PhD, CEO and managing director of Opthea Limited, spoke with our team about the company's clinical trial drug OPT-302 (sozinibercept) at the 2023 ASRS annual meeting.
Euclid founder George Glady passes away at 73
An industrial engineer and entrepreneur, George Glady was a founder of Euclid Systems Corp. and developed the concept of the Ortho-K contact lenses.
ASRS 2023: Nancy Lurker of EyePoint Pharmaceuticals provides update on the Phase 1 DAVIO Trial of EYP-1901
At the 2023 ASRS annual meeting, Nancy Lurker, Executive Vice-Chair of the Board of EyePoint Pharmaceuticals, discussed the subgroup analyses of the Phase 1 DAVIO Trial of EYP-1901.
ASRS 2023: insights on fluid control with faricimab compared to aflibercept in recent studies with Aleksandra Rachiskaya, MD
At the 2023 ASRS annual meeting, Aleksandra Rachiskaya, MD, spoke about time to fluid control with faricimab arms complete compared to aflibercept in recent studies.
New glaucoma treatment development: the cilioscleral technique
Extended dosing with faricimab = greater fluid control compared with aflibercept for DME
Faricimab could lower treatment burden for patients compared to aflibercept
Shedding light on the importance of autophagy in AMD
Novel concept: inner choroid/outer retina neurovascular unit
FDA issues approval for Iveric Bio avacincaptad pegol intravitreal solution for treatment of geographic atrophy
IZERVAY is expected to be available in the United States within 2 to 4 weeks.
ASRS 2023: Ursula Schmidt-Erfurth, MD shares updates from the GALE extension study
At the 2023 ASRS annual meeting in Seattle, Washington, Ursula Schmidt-Erfurth, MD, shared the latest information on the GALE extension study.
